Rick Panicucci, Ph.D.
Rick Panicucci, Ph.D., is the senior vice president of CMC for QED Therapeutics a BridgeBio company. Prior to BridgeBio he served as the vice president of pharmaceutical development services at WuXi STA. In this capacity, Rick provides scientific leadership from developability, formulation development and GMP manufacturing. Previously, Rick was the global head of chemical and pharmaceutical profiling (CPP) at Novartis from 2004 to 2015. His responsibilities included analytics, solid state chemistry and formulation development of all small molecule therapeutics. He also helped develop novel drug delivery technologies for small molecules and large molecules including oligonucleotides. Rick has also led groups in research and development at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb.